Almac Group Discover an Exciting Link between their its Immune Response Assay and Checkpoint Inhibitor Based Therapy

Press/Media: Research

Description

Almac Group’s Diagnostics business has identified a novel immune response mechanism in breast tumors deficient in DNA repair. The current study explains the molecular basis of this 44-gene immune based assay and demonstrates that the genes in the assay reflect activation of the innate immune response cGAS/STING/TBK1/IRF3 pathway in response to DNA damage.

Period10 Oct 2016

Media contributions

1

Media contributions

  • TitleAlmac Group Discover an Exciting Link between their its Immune Response Assay and Checkpoint Inhibitor Based Therapy
    Degree of recognitionInternational
    Media name/outletContract Pharma
    Media typePrint
    Country/TerritoryUnited Kingdom
    Date10/10/2016
    DescriptionAlmac Group’s Diagnostics business has identified a novel immune response mechanism in breast tumors deficient in DNA repair. The current study explains the molecular basis of this 44-gene immune based assay and demonstrates that the genes in the assay reflect activation of the innate immune response cGAS/STING/TBK1/IRF3 pathway in response to DNA damage.
    URLwww.contractpharma.com/contents/view_breaking-news/2016-10-12/almac-diagnostics-assay-identifies-link-to-immune-response-mechanism/
    PersonsPaul Harkin